Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma

Harsha A. Ranganath, Timothy Panella

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The CTLA-4 immune checkpoint inhibitor ipilimumab improves overall survival in metastatic melanoma. Its use in organ transplant recipients has not been studied and has been reported once in the literature. We report the case of a 59-year-old liver transplant patient who was given ipilimumab after previous treatment for advanced melanoma. She did not experience organ rejection, immune-related adverse events, or evidence of tumor regression.

Original languageEnglish (US)
Number of pages1
JournalJournal of Immunotherapy
Volume38
Issue number5
DOIs
StatePublished - May 26 2015

Fingerprint

Melanoma
Transplants
Liver
Survival
Neoplasms
ipilimumab
Transplant Recipients
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. / Ranganath, Harsha A.; Panella, Timothy.

In: Journal of Immunotherapy, Vol. 38, No. 5, 26.05.2015.

Research output: Contribution to journalArticle

@article{b9237786e8c8408a80e6702061f204ff,
title = "Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma",
abstract = "The CTLA-4 immune checkpoint inhibitor ipilimumab improves overall survival in metastatic melanoma. Its use in organ transplant recipients has not been studied and has been reported once in the literature. We report the case of a 59-year-old liver transplant patient who was given ipilimumab after previous treatment for advanced melanoma. She did not experience organ rejection, immune-related adverse events, or evidence of tumor regression.",
author = "Ranganath, {Harsha A.} and Timothy Panella",
year = "2015",
month = "5",
day = "26",
doi = "10.1097/CJI.0000000000000077",
language = "English (US)",
volume = "38",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma

AU - Ranganath, Harsha A.

AU - Panella, Timothy

PY - 2015/5/26

Y1 - 2015/5/26

N2 - The CTLA-4 immune checkpoint inhibitor ipilimumab improves overall survival in metastatic melanoma. Its use in organ transplant recipients has not been studied and has been reported once in the literature. We report the case of a 59-year-old liver transplant patient who was given ipilimumab after previous treatment for advanced melanoma. She did not experience organ rejection, immune-related adverse events, or evidence of tumor regression.

AB - The CTLA-4 immune checkpoint inhibitor ipilimumab improves overall survival in metastatic melanoma. Its use in organ transplant recipients has not been studied and has been reported once in the literature. We report the case of a 59-year-old liver transplant patient who was given ipilimumab after previous treatment for advanced melanoma. She did not experience organ rejection, immune-related adverse events, or evidence of tumor regression.

UR - http://www.scopus.com/inward/record.url?scp=84929668917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929668917&partnerID=8YFLogxK

U2 - 10.1097/CJI.0000000000000077

DO - 10.1097/CJI.0000000000000077

M3 - Article

C2 - 25962109

AN - SCOPUS:84929668917

VL - 38

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 5

ER -